Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466374 · ClinicalTrials.gov registry record · Phase 2
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT01466374: Completed Phase 2 study of Crohn's Disease, sponsored by Bristol-Myers Squibb.
NCT01466374 is a Phase 2 study of Crohn's Disease that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 121 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01466374, a Phase 2 study of Crohn's Disease, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.
Primary Outcome
CDAI: Crohn's Disease Activity Index
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-936557 (Anti-IP-10 Antibody)
Study Locations (20)
Other
- Local Institution - Brussels
- Local Institution - Leuven
- Local Institution - Amiens
- Local Institution - Clichy
- Local Institution - Nice
- Local Institution - Pessac
- Local Institution - Rouen
- Local Institution - Vandœuvre-lès-Nancy
- Local Institution - Budapest
- Local Institution - Budapest
New York
- Nyu Langone Long Island Clinical Research Associates - Great Neck
- Mount Sinai School Of Medicine - New York
California
- Southern California Medical Gastroenterology Group - Santa Monica
Florida
- Shafran Gasteroenterology Center - Winter Park
Louisiana
- Gastroenterology Research Of New Orleans - Hammond
Maryland
- Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr - Chevy Chase
Missouri
- Midwest Center For Clinical Research - Lees Summit
North Carolina
- University Of North Carolina At Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01466374 record still lists
NCT01466374 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01466374 names 20 study sites across 10 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT01466374 about?
NCT01466374 is a clinical study titled "Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease". The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.
What is the current status of trial NCT01466374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2011-12. Estimated completion is 2014-12.
What conditions does trial NCT01466374 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT01466374?
The interventions under investigation include: Placebo (DRUG), BMS-936557 (Anti-IP-10 Antibody) (DRUG).
Who is sponsoring clinical trial NCT01466374?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01466374 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01466374's enrollment target sits among peer trials
121 62nd of 105 higher than 44 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia